Pfizer (NYSE:PFE) Rating Reiterated by Cantor Fitzgerald

Pfizer (NYSE:PFE)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They currently have a $45.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 75.17% from the company’s previous close.

PFE has been the topic of a number of other reports. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Trading Down 0.8 %

NYSE:PFE opened at $25.69 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer has a one year low of $25.61 and a one year high of $41.33. The company has a market cap of $145.47 billion, a PE ratio of 71.36, a PEG ratio of 1.16 and a beta of 0.61. The firm has a 50-day moving average of $27.23 and a 200-day moving average of $28.79.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 EPS. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, equities research analysts expect that Pfizer will post 2.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter valued at approximately $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the third quarter worth $30,000. Main Street Group LTD bought a new position in shares of Pfizer in the fourth quarter worth $30,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.